{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:09:17Z","timestamp":1790636957214,"version":"4.1.0"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurosci."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aims to analyze serum protein changes in patients with myasthenia gravis (MG) via proteomics to identify and validate potential biomarkers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Serum samples were collected from 10 MG patients and 10 healthy controls. The data-independent acquisition (DIA) quantitative proteomics technique was used to measure serum protein levels and identify differentially expressed proteins. Functional enrichment analyses, including Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and gene set enrichment analysis (GSEA), were performed to determine the enrichment trends of the differentially expressed proteins. On the basis of the\n                      <jats:italic>p<\/jats:italic>\n                      values from the enrichment analysis, hierarchical clustering was used to identify significantly enriched pathways in each group. The STRING database was used to construct protein\u2013protein interaction networks of the differentially expressed proteins, identifying the top 50 most closely interacting protein subnetworks and their associated pathways. The target proteins were then validated via mass spectrometry-based targeted proteomics (PRM). Receiver operating characteristic (ROC) curves were plotted for visual analysis. Additionally, serum samples from 20 MG patients and 20 healthy controls (HCs) were collected to validate the proteomic results by enzyme-linked immunosorbent assay (ELISA).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 220 proteins met the exploratory nominal differential-expression criteria between the MG and healthy control groups, including 49 upregulated and 171 downregulated proteins. After Benjamini\u2013Hochberg FDR correction, 138 proteins remained statistically significant, including 23 upregulated and 115 downregulated proteins. Pathway analysis suggested enrichment of complement\/coagulation cascades, tight junctions, regulation of the actin cytoskeleton, and Rap1 signaling. Five prioritized proteins\u2014PROS1, PROC, C4BPA, PFN1, and TLN1\u2014were further evaluated by PRM and ELISA. PRM supported their differential abundance and pathway-level association with complement\/coagulation regulation and cytoskeleton-related processes, but did not demonstrate a causal damage cascade. ROC analysis showed AUC values greater than 0.8 in this exploratory cohort; however, these estimates should be interpreted cautiously because of the limited sample size. ELISA validation further supported increased PROS1, PROC, and C4BPA levels and decreased PFN1 and TLN1 levels in MG patients compared with controls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>PROS1, PROC, C4BPA, PFN1, and TLN1 represent exploratory candidate serum biomarkers for AChR-positive MG and require validation in larger, multicenter cohorts before clinical application.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnins.2026.1810549","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T14:23:55Z","timestamp":1783952635000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["DIA-based serum proteomics of the complement\u2013coagulation cascade identifies candidate biomarkers for myasthenia gravis"],"prefix":"10.3389","volume":"20","author":[{"given":"Zhiguo","family":"Lv","sequence":"first","affiliation":[{"name":"College of Traditional Chinese Medicine, Changchun University of Chinese Medicine","place":["Changchun, Jilin, China"]},{"name":"Department of Encephalopathy, The Affiliated Hospital of Changchun University of Chinese Medicine","place":["Changchun, Jilin, China"]},{"name":"Dingxi Hospital Affiliated to Changchun University of Chinese Medicine","place":["Dingxi, Gansu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yibin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Encephalopathy, The Affiliated Hospital of Changchun University of Chinese Medicine","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianrui","family":"Shao","sequence":"additional","affiliation":[{"name":"College of Traditional Chinese Medicine, Changchun University of Chinese Medicine","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baitong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Encephalopathy, The Affiliated Hospital of Changchun University of Chinese Medicine","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Lu","sequence":"additional","affiliation":[{"name":"The Third Affiliated Clinical Hospital of Changchun University of Chinese Medicine","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Encephalopathy, The Affiliated Hospital of Changchun University of Chinese Medicine","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanying","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Encephalopathy, The Affiliated Hospital of Changchun University of Chinese Medicine","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Encephalopathy, The Affiliated Hospital of Changchun University of Chinese Medicine","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaichen","family":"Wang","sequence":"additional","affiliation":[{"name":"College of Traditional Chinese Medicine, Changchun University of Chinese Medicine","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haorui","family":"Shi","sequence":"additional","affiliation":[{"name":"College of Traditional Chinese Medicine, Changchun University of Chinese Medicine","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meijin","family":"Song","sequence":"additional","affiliation":[{"name":"College of Traditional Chinese Medicine, Changchun University of Chinese Medicine","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianan","family":"Chen","sequence":"additional","affiliation":[{"name":"College of Traditional Chinese Medicine, Changchun University of Chinese Medicine","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Rehabilitation, The Affiliated Hospital of Changchun University of Chinese Medicine","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinchen","family":"Ji","sequence":"additional","affiliation":[{"name":"College of Traditional Chinese Medicine, Changchun University of Chinese Medicine","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DongXu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Encephalopathy, The Affiliated Hospital of Changchun University of Chinese Medicine","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jixiang","family":"Ren","sequence":"additional","affiliation":[{"name":"Affiliated Hospital of Changchun University of Chinese Medicine, College of Traditional Chinese Medicine, Changchun University of Chinese Medicine","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Lu","sequence":"additional","affiliation":[{"name":"Research Center of Traditional Chinese Medicine, The Affiliated Hospital of Changchun University of Chinese Medicine","place":["Changchun, Jilin, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1007\/s00018-016-2372-1","article-title":"Profilin1 biology and its mutation, actin(g) in disease","volume":"74","author":"Alkam","year":"2017","journal-title":"Cell. Mol. Life Sci."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1002\/mus.27774","article-title":"Incidence and causes of overdiagnosis of myasthenia gravis","volume":"67","author":"Andrapalliyal","year":"2023","journal-title":"Muscle Nerve"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"110564","DOI":"10.1016\/j.isci.2024.110564","article-title":"Serum protein biomarker profile distinguishes acetylcholine receptor antibody seropositive myasthenia gravis patients from healthy controls","volume":"27","author":"Bhandage","year":"2024","journal-title":"iScience"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12014-023-09424-x","article-title":"Mass spectrometry-based proteomics as an emerging tool in clinical laboratories","volume":"20","author":"Birhanu","year":"2023","journal-title":"Clin. Proteomics"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/s0161-5890(02)00213-4","article-title":"CCP1-4 of the C4b-binding protein alpha-chain are required for factor I mediated cleavage of complement factor C3b","volume":"39","author":"Blom","year":"2003","journal-title":"Mol. Immunol."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.immuni.2013.06.010","article-title":"T cell-derived protein S engages TAM receptor signaling in dendritic cells to control the magnitude of the immune response","volume":"39","author":"Carrera Silva","year":"2013","journal-title":"Immunity"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"5148","DOI":"10.1021\/acs.jproteome.5c00527","article-title":"Identification of novel protein biomarkers for myasthenia gravis by integrating human proteomics with genetic instruments","volume":"24","author":"Chen","year":"2025","journal-title":"J. Proteome Res."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.1172\/jci29894","article-title":"Myasthenia gravis: past, present, and future","volume":"116","author":"Conti-Fine","year":"2006","journal-title":"J. Clin. Invest."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"776","DOI":"10.3389\/fimmu.2020.00776","article-title":"Autoimmune pathology in myasthenia gravis disease subtypes is governed by divergent mechanisms of immunopathology","volume":"11","author":"Fichtner","year":"2020","journal-title":"Front. Immunol."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/85520","article-title":"Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies","volume":"7","author":"Hoch","year":"2001","journal-title":"Nat. Med."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/nyas.13522","article-title":"Myasthenia gravis: the role of complement at the neuromuscular junction","volume":"1412","author":"Howard","year":"2018","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1110499","DOI":"10.3389\/fimmu.2023.1110499","article-title":"Inflammation and autoimmune myasthenia gravis","volume":"14","author":"Huda","year":"2023","journal-title":"Front. Immunol."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"21229","DOI":"10.1038\/s41598-023-47559-x","article-title":"Residual serum fibrinogen as a universal biomarker for all serotypes of myasthenia gravis","volume":"13","author":"Hussain","year":"2023","journal-title":"Sci. Rep."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.expneurol.2006.06.003","article-title":"Deficiency of decay accelerating factor and CD59 leads to crisis in experimental myasthenia","volume":"202","author":"Kaminski","year":"2006","journal-title":"Exp. Neurol."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/j.1749-6632.2012.06787.x","article-title":"Biomarker development for myasthenia gravis","volume":"1275","author":"Kaminski","year":"2012","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/cells8070671","article-title":"Myasthenia gravis: pathogenic effects of autoantibodies on neuromuscular architecture","volume":"8","author":"Koneczny","year":"2019","journal-title":"Cells"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3389\/fimmu.2020.00212","article-title":"Autoantibody specificities in myasthenia gravis; implications for improved diagnostics and therapeutics","volume":"11","author":"Lazaridis","year":"2020","journal-title":"Front. Immunol."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"a009076","DOI":"10.1101\/cshperspect.a009076","article-title":"Biology of the TAM receptors","volume":"5","author":"Lemke","year":"2013","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref19","doi-asserted-by":"publisher","first-page":"103143","DOI":"10.1016\/j.autrev.2022.103143","article-title":"Seronegative autoimmune diseases: A challenging diagnosis","volume":"21","author":"Lenti","year":"2022","journal-title":"Autoimmun. Rev."},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1580219","DOI":"10.3389\/fimmu.2025.1580219","article-title":"Identification of potential prognostic biomarkers of thymoma with myasthenia gravis based on serum proteomics","volume":"16","author":"Lin","year":"2025","journal-title":"Front. Immunol."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s00415-024-12807-1","article-title":"Factors affecting the diagnostic delay of myasthenia gravis","volume":"272","author":"Marlet","year":"2024","journal-title":"J. Neurol."},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1212\/WNL.41.9.1497","article-title":"Inflammation at the neuromuscular junction in myasthenia gravis","volume":"41","author":"Maselli","year":"1991","journal-title":"Neurology"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1097\/wco.0000000000001088","article-title":"Novel pathophysiological insights in autoimmune myasthenia gravis","volume":"35","author":"Masi","year":"2022","journal-title":"Curr. Opin. Neurol."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/s1474-4422(09)70063-8","article-title":"Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity","volume":"8","author":"Meriggioli","year":"2009","journal-title":"Lancet Neurol."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1526317","DOI":"10.3389\/fimmu.2025.1526317","article-title":"The role of complement in the immunopathogenesis of acetylcholine receptor antibody-positive generalized myasthenia gravis: bystander or key player?","volume":"16","author":"Michailidou","year":"2025","journal-title":"Front. Immunol."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.jneuroim.2015.05.005","article-title":"Novel serum autoantibodies against talin1 in multiple sclerosis: possible pathogenetic roles of the antibodies","volume":"284","author":"Muto","year":"2015","journal-title":"J. Neuroimmunol."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jneuroim.2017.02.008","article-title":"Serum soluble Talin-1 levels are elevated in patients with multiple sclerosis, reflecting its disease activity","volume":"305","author":"Muto","year":"2017","journal-title":"J. Neuroimmunol."},{"key":"ref28","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1002\/mus.27973","article-title":"Activation of the classical complement pathway in myasthenia gravis with acetylcholine receptor antibodies","volume":"68","author":"Ozawa","year":"2023","journal-title":"Muscle Nerve"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/ene.14500","article-title":"Changes in serum complements and their regulators in generalized myasthenia gravis","volume":"28","author":"Ozawa","year":"2021","journal-title":"Eur. J. Neurol."},{"key":"ref30","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1097\/WCO.0b013e328364c079","article-title":"Myasthenia gravis and the neuromuscular junction","volume":"26","author":"Querol","year":"2013","journal-title":"Curr. Opin. Neurol."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1186\/s12885-023-10771-z","article-title":"High expression of Talin-1 is associated with tumor progression and recurrence in melanoma skin cancer patients","volume":"23","author":"Rezaie","year":"2023","journal-title":"BMC Cancer"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/jcm10081736","article-title":"Diagnosis of myasthenia gravis","volume":"10","author":"Rousseff","year":"2021","journal-title":"J. Clin. Med."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.molimm.2022.08.018","article-title":"Complement and myasthenia gravis","volume":"151","author":"Sanderson","year":"2022","journal-title":"Mol. Immunol."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1111\/j.1365-2141.2009.08020.x","article-title":"Activated protein C action in inflammation","volume":"148","author":"Sarangi","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"883743","DOI":"10.3389\/fimmu.2022.883743","article-title":"The hidden side of complement regulator C4BP: dissection and evaluation of its immunomodulatory activity","volume":"13","author":"Serrano","year":"2022","journal-title":"Front. Immunol."},{"key":"ref36","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/0092-8674(95)90520-0","article-title":"The anticoagulation factor protein S and its relative, Gas6, are ligands for the tyro 3\/Axl family of receptor tyrosine kinases","volume":"80","author":"Stitt","year":"1995","journal-title":"Cell"},{"key":"ref37","first-page":"1","article-title":"Chinese guidelines for the diagnosis and treatment of myasthenia gravis (2020 edition)[Chinese]","volume":"28","author":"Ting","year":"2021","journal-title":"Chinese J. Neuroimmunol. Neurol."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1038\/nri916","article-title":"Unravelling the pathogenesis of myasthenia gravis","volume":"2","author":"Vincent","year":"2002","journal-title":"Nat. Rev. Immunol."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/brainsci13091286","article-title":"Diagnosis and Management of Seronegative Myasthenia Gravis: lights and shadows","volume":"13","author":"Vinciguerra","year":"2023","journal-title":"Brain Sci."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/nature11280","article-title":"Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis","volume":"488","author":"Wu","year":"2012","journal-title":"Nature"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s40120-023-00442-3","article-title":"Identification of potential serum protein biomarkers in thymoma with myasthenia gravis after docetaxel treatment","volume":"12","author":"Yang","year":"2023","journal-title":"Neurol Ther."},{"key":"ref42","doi-asserted-by":"publisher","first-page":"49","DOI":"10.3892\/ijmm.2022.5116","article-title":"Talin-1 interaction network in cellular mechanotransduction (review)","volume":"49","author":"Zhao","year":"2022","journal-title":"Int. J. Mol. Med."},{"key":"ref43","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jaut.2013.12.004","article-title":"A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis","volume":"52","author":"Zisimopoulou","year":"2014","journal-title":"J. Autoimmun."}],"container-title":["Frontiers in Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2026.1810549\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T14:23:58Z","timestamp":1783952638000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnins.2026.1810549\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":43,"alternative-id":["10.3389\/fnins.2026.1810549"],"URL":"https:\/\/doi.org\/10.3389\/fnins.2026.1810549","relation":{},"ISSN":["1662-453X"],"issn-type":[{"value":"1662-453X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"article-number":"1810549"}}